Physician profile
Wei M Sun
NPI 1164487450
$1,253.17
in general payments reported to CMS, 2019-2025
19 companies · $179 in 2025
The $179 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $30.25 · 2021: $105 · 2022: $147 · 2023: $36.01 · 2024: $399 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $613.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $205.22 | 2022-2024 | Zeposia |
| Abbvie INC. | $133.98 | 2019-2025 | |
| Madrigal Pharmaceuticals | $125.66 | 2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 2024 | |
| Janssen Scientific Affairs, LLC | $110.32 | 2019 | |
| Medical Device Business Services, INC. | $107.11 | 2019 | |
| Janssen Biotech, INC. | $93.17 | 2019-2022 | |
| Pfizer INC. | $76.86 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.04 | 2019-2022 | |
| Gilead Sciences, INC. | $56.01 | 2019-2021 | |
| Ucb, INC. | $34.76 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.19 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.87 | 2024 | Jardiance |
| Nestle Healthcare Nutrition INC. | $16.97 | 2021 | |
| W. L. Gore & Associates, INC. | $15.42 | 2023 | Gore Cardioform Septal Occluder |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $14.50 | 2024 | |
| Allergan, INC. | $13.08 | 2019 | |
| Braintree Laboratories, INC. | $11.02 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$63,387.65 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.